Long noncoding RNAs as biotargets in cisplatin-based drug resistance
- PMID: 30468082
- DOI: 10.2217/fon-2018-0303
Long noncoding RNAs as biotargets in cisplatin-based drug resistance
Abstract
Since its discovery, cisplatin has become the key drug in chemotherapy for cancers. Nevertheless, chemoresistance in cancers has become an impediment in using cisplatin for cancer treatment. The resistance toward cisplatin is multifaceted as it involves multiple cellular pathways. Ever since the knowledge of long noncoding RNAs as modulators of various molecular pathways came to light, the interest in the biological function of lncRNAs as biomarkers has increased dramatically. Numerous studies have reported the link between the dysregulation of lncRNAs and drug resistance in cancers. More importantly, several lncRNAs were found to be vital in regulating cisplatin resistance. Therefore, this review summarizes the recent efforts in linking between cisplatin resistance and different types of lncRNAs.
Keywords: biomarker; cisplatin; lncRNA; noncoding RNA; platinum.
Similar articles
-
Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.Mol Med Rep. 2017 Oct;16(4):4107-4112. doi: 10.3892/mmr.2017.7081. Epub 2017 Jul 24. Mol Med Rep. 2017. PMID: 29067469
-
Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.J Cell Physiol. 2018 Jun;233(6):5034-5043. doi: 10.1002/jcp.26369. Epub 2018 Jan 2. J Cell Physiol. 2018. PMID: 29219179
-
The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.PLoS One. 2015 May 20;10(5):e0114586. doi: 10.1371/journal.pone.0114586. eCollection 2015. PLoS One. 2015. PMID: 25992654 Free PMC article.
-
LncRNA-mediated regulation of cisplatin response in breast cancer.Pathol Res Pract. 2024 Dec;264:155716. doi: 10.1016/j.prp.2024.155716. Epub 2024 Nov 7. Pathol Res Pract. 2024. PMID: 39536542 Review.
-
Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma.Curr Treat Options Oncol. 2021 Mar 20;22(5):41. doi: 10.1007/s11864-021-00839-y. Curr Treat Options Oncol. 2021. PMID: 33745006 Review.
Cited by
-
HIF2A overexpression reduces cisplatin sensitivity in cervical cancer by inducing excessive autophagy.Transl Cancer Res. 2020 Jan;9(1):75-84. doi: 10.21037/tcr.2019.11.17. Transl Cancer Res. 2020. PMID: 35117160 Free PMC article.
-
PITPNA-AS1/miR-98-5p to Mediate the Cisplatin Resistance of Gastric Cancer.J Oncol. 2022 May 7;2022:7981711. doi: 10.1155/2022/7981711. eCollection 2022. J Oncol. 2022. PMID: 35578599 Free PMC article.
-
Non-coding RNA in drug resistance of gastric cancer.World J Gastrointest Oncol. 2019 Nov 15;11(11):957-970. doi: 10.4251/wjgo.v11.i11.957. World J Gastrointest Oncol. 2019. PMID: 31798777 Free PMC article. Review.
-
LncRNA OTUD6B-AS1 Induces Cisplatin Resistance in Cervical Cancer Cells Through Up-Regulating Cyclin D2 via miR-206.Front Oncol. 2021 Oct 22;11:777220. doi: 10.3389/fonc.2021.777220. eCollection 2021. Front Oncol. 2021. PMID: 34746018 Free PMC article.
-
The identification of a two-gene prognostic model based on cisplatin resistance-related ceRNA network in small cell lung cancer.BMC Med Genomics. 2023 May 15;16(1):103. doi: 10.1186/s12920-023-01536-5. BMC Med Genomics. 2023. PMID: 37189142 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources